Furthermore, the lowest concentration (0.001 μg/mL) of tk-JCPyV VLP-SPBs reduced the viability of another bladder cancer cell line, HT-1376, to 88.7% when administered in combination with GCV. This evidence concerns the gene TKT and urinary bladder carcinoma.